Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 9Terminated 3Recruiting 3Withdrawn 1Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Muscle Invasive Bladder Urothelial Carcinoma 1

Interventions

Fluorodeoxyglucose F18 3pembrolizumab 2sacituzumab govitecan 1ibrutinib 1erdafitinib 1enzalutamide 1enfortumab vedotin 1dynorphin-converting endopeptidase 1avelumab 1apixaban 1Vinblastine 1Surveys and Questionnaires 1Specimen Handling 1Radiosurgery 1Pancreatectomy 1Paclitaxel 1Nivolumab 1Methotrexate 1Magnetic Resonance Imaging 1JNJ-64619178 1JNJ-64264681 1Inosine Monophosphate 1Health Information Exchange 1Genetic Testing 1Genetic Counseling 1Gemcitabine 1Focus Groups 1Enoxaparin 1Docetaxel 1Cystoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × erdafitinib × Genitourinary × Clear all
NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

Brigham and Women's Hospital

Phase EARLY_PHASE1 Enrolling by invitation
18 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡